BackgroundA recent randomized control trial in children with steroid-resistant nephrotic syndrome revealed that two doses of rituximab did not reduce proteinuria.Case characteristicsA 14-month-old boy developed refractory steroid-resistant nephrotic syndrome due to focal segmental glomerulosclerosis.ObservationThe patient achieved complete remission 11 months after disease onset following eight doses of rituximab combined with steroids and cyclosporine.MessageLong-lasting B cell depletion with repeated rituximab administrations may be required to achieve complete remission in patients with steroid-resistant nephrotic syndrome and massive proteinuria. |